Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nanobiotix

Europe’s best-performing stocks of 2026 — including one up by 947%

From Swedish photonics to French satellites and British fuel cells, meet this year's top-performing equities across sectors.

Euronews · May 12

This Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?

Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength. Shares are trading at new all-time highs. NBTX has surged 440% over the past year. Nanobiotix has a Trend Seeker “Buy” signal and strong technical indicators, but it remains highly volatile. Today’s Featured Stock Valued at...

Barchart · Oct 9, 2025

Top 2 Health Care Stocks That May Keep You Up At Night This Month

As of Oct. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga · Oct 2, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer

Nanobiotix SA (NASDAQ:NBTX) on Tuesday announced updated data from cohorts 1 and 2 of Study 1100 Phase 1 dose escalation and expansion trial evaluating JNJ-1900 (NBTXR3) activated by radiation therapy (RT) followed by anti-PD-1 immune checkpoint inhibitors (ICI) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma…

Benzinga · Sep 30, 2025

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

Benzinga · Sep 18, 2025

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga · Sep 7, 2022

Nanobiotix's Radiotherapy Combo Therapy Shows Boosted Anti-Tumor Activity In Preclinical Studies

Nanobiotix SA (NASDAQ: NBTX)

Benzinga · Apr 12, 2022

Read news from The Economist, FT, and more,
with one subscription

Nanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient

Nanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology.

Benzinga · Feb 10, 2022

Coverage From

People

Jim Van Meerten

51 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

US Food and Drug Administration

63 stories

Ionis

20 stories

Ionis Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.